Coronavirus Fighter Gilead Sciences Might Be Expensive, but It’s Still Worth Owning

Gilead Sciences (GILD) has positioned itself at the front line in the global war against COVID-19. The biotech’s experimental drug remdesivir is currently in two Gilead sponsored Phase 3 trials in over 90 locations, and two further investigator sponsored Phase 3 trials in China. The drug is currently registered in 11 ongoing trials, from which a handful of data readouts are expected in the next 2 to 6 weeks.So far, remdesivir has shown powerful in vitro efficacy against RNA viruses in cell-based assays and evidence of efficacy in both in California and Washington states; Additionally, there has also been some …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.